Non Small Cell Lung Cancer

AmoyDx PLC Panel gets Japanese approval as companion diagnostic for NSCLC
The AmoyDx PLC Panel has been approved in Japan for the identification of activating alterations in seven driver genes, including RET, to be used in identifying patients whose NSCLC is likely to respond to treatment with selpercatinib.
March 27, 2023
Cancer Lung 3 D Black Social
Guardant Health shares rise on Q4 growth in clinical, biopharma testing
For Q4, the firm reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021.
February 24, 2023
Graph Financial Results Bar Chart Social
Oncocyte sells 70% stake in Razor Genomics to Dragon Scientific
The deal allows Razor Genomics to continue offering DetermaRx, a molecular stratification test to identify patients with IA-IIA non-squamous NSCLC who may be at low or high risk of having a recurrence.
February 22, 2023
Hands Shaking Deal Social
CAR-T cell therapies eliminate residual, drug-resistant lung cancer cells in preclinical tests
The analysis showed that CD70, a cell surface protein normally found on immune cells, is highly overexpressed by drug-resistant cells and the residual cells that remain immediately after treatment with an EGFR TKI.
February 13, 2023
Cancer Lung 3 D Black Social
Guardant NSCLC biomarker test to incorporate Lunit’s AI-based scoring algorithm
The integrated Lunit Scope PD-L1 algorithm will augment the TissueNext test’s detection of the PD-L1 biomarker in tissue samples using an AI-based scoring system.
February 1, 2023
Computer Ai Artificial Illustration Social
Thermo Fisher Scientific, AstraZeneca to develop solid tissue and blood-based CDx for NSCLC
The companion diagnostic leverages Thermo Fisher’s Oncomine Dx Express Test on its Genexus Dx System, a fully integrated next-generation sequencing platform, with an automated specimen-to-report workflow that provides results in 24 hours.
January 24, 2023
Hands Shaking Deal Social
Agilent, Quest extend access to NGS liquid biopsy CDx for NSCLC
The agreement between Agilent and Quest aims to enable broader adoption of ctDx First, a single-site premarket approved test performed at the Resolution Bioscience CLIA-certified laboratory in Kirkland, WA.
January 23, 2023
Lung Cancer2 Social
Foundation Medicine obtains FDA approval for NSCLC CDx
The blood-based test’s first group approval improves physicians’ ability to identify patients in this population for treatment with certain FDA-approved tyrosine kinase inhibitors, Foundation Medicine said.
December 21, 2022
Fda Button Social
Agilent announces FDA approval for non-small cell lung cancer CDx
Resolution ctDx First is a liquid biopsy next-generation sequencing (NGS) assay; it has also been approved by the FDA for tumor profiling of the epidermal growth factor receptor (EGFR) gene in patients with NSCLC.
December 13, 2022
Lung Cancer Hotspot Social
Cofactor Genomics kicks off study of multidimensional immune biomarker assay for NSCLC
The firm's OncoPrism diagnostic platform generates multidimensional immune biomarkers using predictive immune modeling.
December 15, 2022
Lung Cancer Social
Qiagen obtains FDA approval for NSCLC companion diagnostic assay
Therascreen KRAS is a tissue-based polymerase chain reaction (PCR) assay designed to identify NSCLC patients likely to respond to treatment with Mirati Therapeutics’ Krazati (adagrasib).
December 13, 2022
Cancer Lung 3 D Black Social
OncoHost preparing launch of proteomics diagnostics platform for cancer, immunotherapy
The appointments come ahead of the company's launch of its AI-powered diagnostic platform called PROphet.
October 3, 2022
Lung Cancer2 Social
Page 1 of 4
Next Page